CliffBio
small molecule

OZOBAX DS

BACLOFEN

Loss of exclusivity—loss of exclusivity
CompanyMETACEL PHARMACEUTICALS LLC

Drug detail

Brand nameOZOBAX DS
Active ingredientBACLOFEN
Strength10MG/5ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2023
Marketing statusRX

More from METACEL PHARMACEUTICALS LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

OZOBAX DS patent cliff — loss of exclusivity — | CliffBio